Join to View Full Profile
201 North Broadway StreetViragh BLDG 5th FLBaltimore, MD 21287
Phone+1 410-955-8964
Fax+1 410-367-2194
Dr. Lipson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2008 - 2011- Johns Hopkins UniversityResidency, Internal Medicine, 2005 - 2008
Icahn School of Medicine at Mount SinaiClass of 2005
Certifications & Licensure
FL State Medical License 2022 - Present
DC State Medical License 2012 - 2026
MD State Medical License 2008 - 2026
PA State Medical License 2024 - 2026
VA State Medical License 2021 - 2026
DE State Medical License 2022 - 2023
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
Clinical Trials
- Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma Start of enrollment: 2018 Nov 27
- Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers Start of enrollment: 2019 Nov 08
- Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer Start of enrollment: 2024 Jul 24
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- BIO25-026: Innovating a Digital Patient Navigation Platform (DPNP) to Help Patients With Melanoma Access Multidisciplinary Cutaneous Oncology Care.Govind Warrier, Shannon Kehrli, Renee Ofori, Hao Wang, Daniel Matiaudes
Journal of the National Comprehensive Cancer Network. 2025-03-28 - Anti-CTLA4 therapy leads to early expansion of a peripheral Th17 population and induction of Th1 cytokines.Mari Nakazawa, Soren Charmsaz, Elsa Hallab, Mike Fang, Chester Kao
Cancer Immunology Research. 2025-03-27 - Gut microbiome features associate with immune checkpoint inhibitor response in individuals with non-melanoma skin cancers: an exploratory study.Yujie Zhao, Jacqueline T Ferri, James R White, Megan D Schollenberger, Kim Peloza
Microbiology Spectrum. 2025-03-04
Journal Articles
- From Validity to Clinical Utility: The Influence of Circulating Tumor DNA on Melanoma Patient Management in a Real‐World SettingKaren B Bleich, William H Sharfman, Steven P Rowe, Evan J Lipson, Megan D Schollenberger, Molecular Oncology
- Nodular Regenerative Hyperplasia Associated with Immune Checkpoint BlockadeEvan J Lipson, Michael I Brener, Jaclyn LoPiccolo, James P Hamilton, Hepatology
Press Mentions
Toxic Trade-OffsMarch 16th, 2023- Evan Lipson, MD, on Nivolumab plus Relatlimab for Advanced MelanomaJuly 14th, 2022
- ASCO: Nivolumab, Relatlimab Combo Slows Advanced MelanomaMay 30th, 2021
- Join now to see all
External Links
- Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/evan-lipson
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
